France Oncology Clinical Trials Market Report 2022 to 2030

France Oncology Clinical Trials Market Analysis

$ 3999

The France oncology clinical trials market is projected to grow from $347.9 Mn in 2022 to $494.7 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of cancer cases, the modern healthcare system in the nation, and a supportive regulatory framework. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Transgene & Ipsen.

ID: IN10FRCT006 CATEGORY: Clinical Trials GEOGRAPHY: France AUTHOR: Vidhi Upadhyay

Buy Now

France Oncology Clinical Trials Market Executive Summary

The France oncology clinical trials market is projected to grow from $347.9 Mn in 2022 to $494.7 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. In 2020, France participated in 319 of the 2,972 clinical trials completed globally, accounting for 11%. Cancers of the prostate, breast, lung, colorectum (big bowel), and uterus are the most prevalent in France. According to Globocan 2020, the number of new cases of cancer in France was 4,67,965 with Breast cancer contributing to 12.4%, prostate cancer at 14.1%, and Lung cancer at 10.3% of the same.

Oncology clinical trials include studying innovative cancer medications or therapy combinations to determine their safety and effectiveness. A number of cancer clinical trials are now happening in France, most of which are being conducted by hospitals, research organizations, or pharmaceutical businesses. France is home to several of Europe's premier cancer research facilities, including the Gustave Roussy Cancer Campus, the Institut Curie, and the Lyon Cancer Research Center. These institutes are well-known for performing cutting-edge research and creating novel cancer therapies. France is participating in a number of novel clinical studies, such as early-stage trials for new drug candidates, combination medicines, and immunotherapy trials.

In December 2022, Affimed N.V. (a clinical-stage immuno-oncology business) announced the clearance of a phase 1 study of afm28 in relapsed/ refractory acute myeloid leukaemia in France.

france oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

France is home to some of Europe's best cancer research institutes, attracting numerous multinational pharmaceutical firms and researchers to undertake clinical studies there. These institutes are well-known for performing cutting-edge research and creating novel cancer therapies. France offers an advantageous regulatory framework for clinical trials, making it an appealing place for cancer research investigations. The nation has adopted the EU Clinical Trial Regulation, which assures that all clinical trials adhere to high ethical and scientific criteria. Owing to the rising prevalence of cancer cases, France has a huge patient population and is noted for its high clinical trial patient recruitment rates. This is owing to the modern healthcare system in the nation, as well as the high level of patient knowledge and willingness to engage in research projects.

Market Restraints

France faces rising competition from other nations as several countries in Europe and throughout the globe as they lay emphasis on expanding their cancer research capacity. This may make attracting foreign pharmaceutical firms and researchers to undertake clinical trials in France more difficult. While France offers a favorable regulatory environment for clinical trials, the regulatory structure may be complicated and time-consuming, which may dissuade some firms from conducting clinical studies. In France, funding for cancer clinical trials is limited, making it difficult to get financing for research investigations.

Competitive Landscape

Key Players

Roche Holding AG
Pfizer Inc.
Novartis AG
Sanofi S.A.
AstraZeneca
Merck & Co., Inc.
Bristol-Myers Squibb Company
CNS Pharmaceuticals, Inc
Affimed N.V
Servier (FRA)
Ipsen (FRA)
Pierre Fabre (FRA)
Transgene (FRA)

Notable Deals

December 2022, Affimed N.V. (a clinical-stage immuno-oncology business) announced the clearance of a phase 1 study of afm28 in relapsed/ refractory acute myeloid leukaemia in France
November 2022, CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that the first patient in Europe enrolled and dosed in France
November 2021, Transgene and NEC report early favorable results from Phase I investigations of TG4050, a unique customized neoantigen cancer vaccination

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.